This article is about the<unk> , or androgen receptor (AR) antagonists. In the 1960s, the first<unk> was<unk> d.<unk>  antagonise the androgen receptor (AR) and thereby block the biological effects of testosterone and dihydrotestosterone (DHT).<unk>  are important for men with hormonally responsive diseases like prostate cancer, benign prostatic hyperplasia (BHP), acne, seborrhea, hirsutism and androgen alopecia.<unk>  are mainly used for the treatment of prostate diseases. Research from 2010 suggests that ARs could be linked to the disease progression of triple-negative breast cancer and salivary duct carcinoma and that<unk>  can potentially be used to treat it.<unk>  are small molecules and can be either steroidal or nonsteroidal depending on ligand chemistry. Steroidal<unk>  share a similar steroid structure, while nonsteroidal<unk>  (NSAAs) may have structurally distinctive pharmacophores. Only a limited number of compounds are available for clinical use despite the fact that a very large variety of<unk> compounds have been<unk> d and researched.
Discovery and development of antiandrogens
Breast enlargement supplement
Androgen suppression
Structure–activity relationships of anabolic steroids
treatment of Body image disturbance
Fertility preservation
Comparison of bicalutamide with other antiandrogens
risks of Erectile dysfunction